Research

Department's scope of research is focused on pharmacokinetic studies, including clinical pharmacokinetics and pharmacogenetic studies.

Pharmacokinetic studies:

• Clinical significance of mycophenolic acid pharmacokinetic studies in immunosuppressive therapy in renal transplant patients
• Pharmacokinetics and pharmacodynamics of mycophenolic acid in children with nephrotic syndrome treated with mycophenolate mofetil
• Kinetics and pharmacokinetics of treosulfan and its activation products
• Monitoring of etoposide in children prepared for bone marrow transplantation
• Monitoring and pharmacokinetics of voriconazole in children undergoing antifungal therapy
• Development of population pharmacokinetic models
• Assessment of the pharmacokinetic interaction between clopidogrel and statins
• Pharmacokinetic study of second generation fluoroquinolones in an animal model
• Determination of the concentrations of selected proteins and biological drugs (monoclonal antibodies) in the serum of patients with small cell lung cancer

Pharmacogenetic studies:

• Genetic polymorphism of thiopurine methyltransferase and its clinical significance in the treatment of acute lymphoblastic leukemia
• Analysis of levels of endogenous glucocorticoids and their metabolites as a criterion for the diagnosis of metabolic disorders in humans, including the assessment of the genetic polymorphism in 11β-hydroxysteroid dehydrogenase 2
• The effect of genetic polymorphism of cytochrome P450 on the pharmacokinetics of clopidogrel and its metabolites in the context of the study of resistance to clopidogrel
• The activity of 11β-hydroxysteroid dehydrogenase 2 in pregnant women with hypertension
• The effect of genetic polymorphism of CYP2C8 and CYP2C9 isoenzymes on the pharmacokinetics of chiral drugs
• Genetic polymorphism of the vitamin D receptor and analysis of the concentrations of hydroxylated metabolites of vitamin D in patients with cardiovascular diseases